Introduction
Ellipticine (5,11-dimethyl-6H-pyrido[4,3-b] carbazole; Fig. 1 ) is a natural plant alkaloid originally isolated from Ochrosia elliptica of the Apocynaceae family that has been found to be a potent antitumour agent (for a review, see Garbett & Graves, 2004) . Many of its more soluble derivatives, which have different DNA-binding affinities, show antitumour and cytotoxic effects and exhibit promising results in the treatment of breast-cancer metastases, kidney sarcomas, brain tumours and myeloblastic leukaemia (Stiborová et al., 2001) . Although a multimodal mechanism of action on DNA is accepted (Auclair, 1987) , the effects of ellipticine derivatives are considered to mainly be based on DNA intercalation and/or the inhibition of topoisomerase II. Unfortunately, the exact mechanism remains unclear as a faithful binding mode has not been fully depicted to date. An early X-ray crystallographic structure of ellipticine complexed with a self-complementary ribodinucleoside monophosphate (Jain et al., 1979; NDB code DRBB11) shows that the drug binds as a parallel base-stacking intercalator, similar to cryptolepine (Lisgarten et al., 2002) , actinomycin (Shinomiya et al., 1995) and acridine-type drugs (Adams et al., 1999) , which intercalate parallel to the base-pair hydrogen bonds and stack its aromatic rings into the DNA bases. This type of binding would be in keeping with the hydrodynamic studies that assigned to ellipticine an unwinding angle equivalent to that of the parallel base-stacking intercalator ethidium bromide (Kohn et al., 1975) , accepted as being approximately 26 (Wang, 1974) . However, because of the short length of the oligonucleotide used by Jain and coworkers, it has been questioned whether that structure represents the real DNA-binding mode (Garbett & Graves, 2004) . Also, molecular-dynamics simulations suggested an alternative binding mode for one of its most studied derivatives, 9-hydroxyellipticine (Elcock et al., 1996) . According to these, 9-hydroxyellipticine would # 2005 International Union of Crystallography Printed in Denmark -all rights reserved Figure 1 Chemical structure of ellipticine and the 9-hydroxyellipticine derivative.
intercalate in an orientation perpendicular to the long base-pair axis. As every derivative may have a different binding mode, extensive and accurate information on how the drugs of this family interact with DNA is needed in order to understand their mechanism of action.
Here, we report the crystal structure determination of ellipticine in complex with a 6 bp DNA at 1.5 Å resolution, compare it with the previous crystallographic study of the same drug within a 2 bp structure and discuss the effect of ellipticine intercalation on DNA unwinding and lengthening.
Materials and methods

Crystallization and data collection
Crystallization conditions were screened using the Nucleic Acid Mini Screen (Berger et al., 1996) . Yellow hexagonal crystals were grown at 293 K by the hanging-drop vapour-diffusion technique by mixing 2.0 ml 5 mM ellipticine, 1.0 ml 1.5 mM d(CGATCG) 2 and 1.0 ml crystallization solution (12% MPD, 40 mM sodium cacodylate pH 5.5, 20 mM cobalt hexammine, 12 mM sodium chloride and 80 mM potassium chloride) equilibrated against 500 ml 78% MPD. Both lowand high-resolution data sets were collected on a 130 mm MAR CCD detector (MAR Research) from a single crystal kept at 120 K using synchrotron radiation ( = 0.976 Å ) at the ESRF (Grenoble) microfocus beamline ID13. Data were indexed, integrated and scaled with the XDS package (Kabsch, 1993) , yielding an R merge of 8.7% and a completeness of 99.6% in the resolution range 16.7-1.5 Å . Datacollection statistics are shown in Table 1 .
Structure solution and refinement
The structure was solved by molecular replacement with AMoRe (Navaza, 1994) using the DNA coordinates of the d(CGTACG)-D232 structure (Shui et al., 2000 ; NDB code DD0018) as a starting model. Reflections within the resolution range 16.7-3.0 Å were used for rotation-and translation-function calculations. One clear solution was found with a correlation coefficient of 54.8% and a crystallographic R factor of 46.8% (values for the second highest peak are 46.0 and 49.6%, respectively). Refinement followed with REFMAC5 (Murshudov et al., 1999) . The optimum orientation of the intercalated ellipticine was identified by placing the drug in each of the four possible positions and refining until the best fit and corresponding best R factor and R free were found. At this stage, an iterative refinement procedure was carried out using REFMAC5 with ARP/ wARP (Perrakis et al., 1999) , interspersed with inspection of electrondensity maps, water positioning and manual model rebuilding with TURBO-FRODO (Roussel & Cambillau, 1989) . All data were used (16.7-1.5 Å ) with no low-resolution or cutoff. A randomly selected 221 reflections (5%) were set aside for R free calculations. The final refinement statistics are shown in 
Results and discussion
The ellipticine-d(CGATCG) 2 complex crystallizes in the hexagonal space group P6 5 , with unit-cell parameters a = 24.86, b = 24.86, c = 78.86 Å . The asymmetric unit consists of a DNA duplex plus two drug molecules. The self-complementary hexamer adopts the doublehelical B-DNA conformation with an ellipticine molecule intercalated between the CpG steps at both ends of the duplex (Fig. 2a ). All atoms for both DNA and drug molecules have been modelled in and are well defined, as indicated by the quality of the electrondensity maps (Fig. 2b) . Inspection of 2F o À F c density maps contoured at the 4.0 level revealed three putative hexammine cobalt molecules. The exact location of their amine moieties could not be determined and only the metal atom was added to the final model.
As might be expected owing to its shape and planar structure, ellipticine intercalates by stacking interactions with DNA base pairs (Fig. 2c ). By these stacking interactions, ellipticine is aligned with its major axis parallel to the Watson-Crick hydrogen bonds of the base pairs. Despite sharing a common shape with cryptolepine, the different distribution of N atoms and methyl residues in ellipticine leads to a slightly different intercalation (Lisgarten et al., 2002) . Nitrogen N2 of both drug molecules faces the major groove of the DNA. None of the drug molecules are hydrogen-bonded to the DNA. Whereas one ellipticine molecule (E1) is kept in the intercalation site solely by stacking interactions, nitrogen N2 of the other molecule (E2) participates in a hydrogen bond with a water molecule (15W). The structure confirms that ellipticine has a strong preference for the d(GpC)-d(CpG) site, as no drug molecules are sandwiched in the d(ApT)-d(TpA) site. The three hydrogen bonds between G and C bases guarantee a tighter and thus more favourable site for intercalating a planar structure such as ellipticine.
In essence, the intercalation mode is similar to that described by Jain et al. (1979) in the structure of the complex of ellipticine with a self-complementary ribodinucleoside monophosphate. When superimposing the X-ray structures (Fig. 2d) , the r.m.s. deviation for the positions of common C1 0 atoms is 0.87 Å . They have similar sugar-phosphate backbone geometry, with a mixed sugar-puckering pattern C3 0 -endo/C2 0 -endo at the immediate site of drug intercalation. There is only a minor deviation of the ellipticine molecule position.
The ellipticine-d(CGATCG) 2 complex is tightly packed in the crystal, allowing only a 23% solvent content (27 water molecules in the final asymmetric unit). A peculiar end-to-side interaction between asymmetric units is the basis of the crystal packing. The C1-G6 base pair of one end of the complex invades the major groove of a neighbouring complex at the A3pT4 step and is held there by a direct hydrogen bond between the N1 of guanine G6 and O4 0 of adenine A3 and two water-mediated hydrogen bonds (O6 of guanine G6 and O1 of phosphate from thymine T4, through water 18 W; O3 0 of cytosine C5 and O1 of phosphate from guanine 6A, through water 3W). This pattern of interactions is repeated in a reciprocal way, so that every complex is both invaded and an invader at each end, as shown in Fig. 2(e) . Water molecules mediate the other packing interactions between complexes.
As a result of the intercalation, the DNA is unwound and lengthened (Fig. 3) . The DNA in the complex has a B-like conformation with Watson-Crick base pairing. However, in accommodating the intercalated ellipticine molecule, the DNA assumes conformational parameters that are significantly different from average B-DNA values. The DNA helical twist at the C1 A pG2 A -G6 B pC5 B and C5 A pG6 A -G2 B pC1 B intercalation sites is 21.4 and 21.9 , respectively. This is an unwinding angle of approximately 14 with respect to standard B-DNA at the intercalation steps. (Lavery & Sklenar, 1988) . Black lines indicate the expected inter-base-pair rotation angles and distances for an average drug-free B-DNA with the same sequence generated with TURBO-FRODO (Roussel & Cambillau, 1989) . Coloured blocks with white values depict the actual winding and length between contiguous base-pairs in our structure. Overall differences are given in black. both intercalation sites, the bases are separated by 6.9 Å . To achieve this major opening of the bases, the sugar-phospate backbone is distorted as discussed earlier.
Although the structure of ellipticine in complex with DNA strongly suggests a similar binding for its derivatives, other binding modes for the members of the ellipticine family cannot be ruled out. They may be as diverse as their cytotoxic or anticancer effects. Further structural studies should confirm if the binding mode described here also applies for the whole drug family.
